MGX insider transaction filings
Metagenomi Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-11. Screen MGX transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 4 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 1 filing by 1 insider — 20,000 shares, $23,401 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 3 legs across 3 filings by 3 insiders — 4,409 shares, $5,107 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: purchase of 19,883 shares @ $1.17 ($23,263) by Reid Laurence, filed 2026-09-11.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Reid Laurence — Director | 1 | 2 legs · 20,000 sh · $23,401 | — | — |
| Irish Jian — See Remarks, Director | 1 | — | 1 leg · 2,140 sh · $2,479 | — |
| Wapnick Pamela — Chief Financial Officer | 1 | — | 1 leg · 1,911 sh · $2,214 | — |
| Wein Matthew — See Remarks | 1 | — | 1 leg · 358 sh · $415 | — |
Recent Form 4 filings — Metagenomi Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-11 | 4 | Reid Laurence — Director | Purchase (P): 19,883 @ $1.17 · Purchase (P): 117 @ $1.18 | EDGAR |
| 2026-09-10 | 4 | Wein Matthew — See Remarks | Sale (S): 358 @ $1.16 | EDGAR |
| 2026-09-10 | 4 | Irish Jian — See Remarks, Director | Sale (S): 2,140 @ $1.16 | EDGAR |
| 2026-09-10 | 4 | Wapnick Pamela — Chief Financial Officer | Sale (S): 1,911 @ $1.16 | EDGAR |
| 2026-06-11 | 4 | Eckhardt Juergen — Director | Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Reid Laurence — Director | Grant/award (A): 17,400 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Dere Willard H — Director | Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | BJERKHOLT ERIC — Director | Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Wapnick Pamela — Chief Financial Officer | Sale (S): 2,884 @ $1.30 | EDGAR |
| 2026-06-10 | 4 | Irish Jian — See Remarks, Director | Sale (S): 3,737 @ $1.30 | EDGAR |
| 2026-06-10 | 4 | Wein Matthew — See Remarks | Sale (S): 558 @ $1.30 | EDGAR |
| 2026-04-03 | 4 | Irish Jian — See Remarks, Director | Grant/award (A): 46,000 @ $0 · Grant/award (A): 276,000 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Wein Matthew — See Remarks | Grant/award (A): 11,000 @ $0 · Grant/award (A): 68,000 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Wapnick Pamela — Chief Financial Officer | Grant/award (A): 24,000 @ $0 · Grant/award (A): 144,000 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Wapnick Pamela — Chief Financial Officer | Sale (S): 1,581 @ $1.60 | EDGAR |
| 2026-03-09 | 4 | Wein Matthew — See Remarks | Sale (S): 482 @ $1.60 | EDGAR |
| 2026-03-09 | 4 | Irish Jian — Chief Executive Officer, Director | Gift (G): 228,462 @ $0 · Sale (S): 1,607 @ $1.60 | EDGAR |
| 2025-12-08 | 4 | Thomas Brian C. — Director | Sale (S): 3,830 @ $1.77 | EDGAR |
| 2025-12-08 | 4 | Wein Matthew — See Remarks | Sale (S): 199 @ $1.77 | EDGAR |
| 2025-12-08 | 4 | Wapnick Pamela — Chief Financial Officer | Sale (S): 1,576 @ $1.77 | EDGAR |
| 2025-12-08 | 4 | Irish Jian — Chief Executive Officer, Director | Sale (S): 1,602 @ $1.77 | EDGAR |
| 2025-12-01 | 4 | Thomas Brian C. — Director | Sale (S): 2,701 @ $1.81 | EDGAR |
| 2025-12-01 | 4 | Wapnick Pamela — Chief Financial Officer | Sale (S): 1,576 @ $1.81 · Grant/award (A): 120,000 @ $1.60 | EDGAR |
| 2025-12-01 | 4 | Irish Jian — Chief Executive Officer, Director | Sale (S): 1,602 @ $1.81 · Grant/award (A): 37,500 @ $1.60 · Grant/award (A): 211,000 @ $1.60 · Grant/award (A): 225,000 (derivative) @ $0 | EDGAR |
| 2025-12-01 | 4 | Wein Matthew — See Remarks | Sale (S): 199 @ $1.81 · Grant/award (A): 96,000 @ $1.60 | EDGAR |
| 2025-09-02 | 4 | Reid Laurence — Director | Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Eckhardt Juergen — Director | Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Dere Willard H — Director | Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | BJERKHOLT ERIC — Director | Grant/award (A): 8,572 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Wein Matthew — See Remarks | Sale (S): 199 @ $1.75 | EDGAR |
| 2025-06-09 | 4 | Wapnick Pamela — Chief Financial Officer | Sale (S): 1,576 @ $1.75 | EDGAR |
| 2025-06-09 | 4 | Thomas Brian C. — Chief Executive Officer, Director | Sale (S): 10,785 @ $1.75 | EDGAR |
| 2025-06-09 | 4 | Irish Jian — See Remarks, Director | Sale (S): 6,390 @ $1.75 | EDGAR |
| 2025-06-09 | 4 | Noonberg Sarah B. — Chief Medical Officer | Sale (S): 5,239 @ $1.75 | EDGAR |
| 2025-04-03 | 4 | Wapnick Pamela — Chief Financial Officer | Grant/award (A): 14,000 @ $0 · Grant/award (A): 84,000 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Thomas Brian C. — Chief Executive Officer, Director | Grant/award (A): 32,000 @ $0 · Grant/award (A): 196,000 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Irish Jian — See Remarks, Director | Grant/award (A): 23,000 @ $0 · Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Wein Matthew — See Remarks | Grant/award (A): 3,650 @ $0 · Grant/award (A): 3,775 @ $0 · Grant/award (A): 21,875 (derivative) @ $0 · Grant/award (A): 22,725 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Noonberg Sarah B. — Chief Medical Officer | Grant/award (A): 14,000 @ $0 · Grant/award (A): 84,000 (derivative) @ $0 | EDGAR |
| 2025-03-07 | 4 | Wein Matthew — See Remarks | Sale (S): 930 @ $1.87 | EDGAR |
| 2025-03-07 | 4 | Wapnick Pamela — Chief Financial Officer | Sale (S): 1,808 @ $1.87 | EDGAR |
| 2025-02-05 | 4 | BJERKHOLT ERIC — Director | Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2024-12-06 | 4 | Wapnick Pamela — Chief Financial Officer | Sale (S): 1,559 @ $1.86 | EDGAR |
| 2024-09-06 | 4 | Wapnick Pamela — Chief Financial Officer | Sale (S): 6,265 @ $2.88 | EDGAR |
| 2024-04-03 | 4 | Harnest Simon — See Remarks | Grant/award (A): 11,552 @ $0 · Grant/award (A): 48,575 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | Delaney Simren — See Remarks | Grant/award (A): 6,931 @ $0 · Grant/award (A): 29,145 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | Thomas Brian C. — Chief Executive Officer, Director | Grant/award (A): 118,992 @ $0 · Grant/award (A): 500,323 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | Noonberg Sarah B. — Chief Medical Officer | Grant/award (A): 57,763 @ $0 · Grant/award (A): 242,875 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | Borges Luis — Chief Scientific Officer | Grant/award (A): 69,316 @ $0 · Grant/award (A): 291,450 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | Dere Willard H — Director | Grant/award (A): 78,636 (derivative) @ $0 | EDGAR |
Recent 8-K events — Metagenomi Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-22 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-10 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-11 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-01 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement | EDGAR |
| 2025-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-11 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MGX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →